1.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
2.
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials
by Eron, Joseph J, Prof
The Lancet infectious diseases, 2013, Vol.13 (7), p.587-596
3.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised control...
by Lennox, Jeffrey L, Prof
The Lancet (British edition), 2009, Vol.374 (9692), p.796-806
4.
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
by Grinsztejn, Beatriz, MD
The Lancet (British edition), 2007, Vol.369 (9569), p.1261-1269
5.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
by Lazzarin, Adriano, Prof
The Lancet (British edition), 2007, Vol.370 (9581), p.39-48
6.
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial
by Pollard, Richard B, MD
The Lancet infectious diseases, 2014, Vol.14 (4), p.291-300
7.
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomise...
by Clotet, Bonaventura, Dr
The Lancet (British edition), 2007, Vol.369 (9568), p.1169-1178
8.
Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
by Molina, Jean-Michel, Prof
The Lancet (British edition), 2015, Vol.385 (9973), p.1098-1106
9.
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled...
by Sulkowski, Mark, Prof
The Lancet infectious diseases, 2013, Vol.13 (7), p.597-605
